BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Saturday, February 14, 2026
Home
»
Authors
» Jennifer Boggs
Jennifer Boggs
Articles
ARTICLES
Sirtris' Series B Gets $27M For Class III HDAC Research
March 8, 2005
By
Jennifer Boggs
Sirtris' Series B Gets $27M For Class III HDAC Research
March 8, 2005
By
Jennifer Boggs
Neurochem Raising $61M For Alzhemed's Phase III Studies
March 7, 2005
By
Jennifer Boggs
Neurochem Raising $61M For Alzhemed's Phase III Studies
March 7, 2005
By
Jennifer Boggs
Allos Secures $50M Investment For Efaproxyn Phase III Program
March 4, 2005
By
Jennifer Boggs
Allos Secures $50M Investment For Efaproxyn Phase III Program
March 4, 2005
By
Jennifer Boggs
Osel Gains Lead Bacteria-Based Product Through Licensing Deal
March 3, 2005
By
Jennifer Boggs
Osel Gains Lead Bacteria-Based Product Through Licensing Deal
March 3, 2005
By
Jennifer Boggs
Discovery Acquires Biofrontera, Expects To Lose Money In 2005
March 2, 2005
By
Jennifer Boggs
Discovery Acquires Biofrontera, Expects To Lose Money In 2005
March 2, 2005
By
Jennifer Boggs
View All Articles by Jennifer Boggs
